May 31, 2019
Mitsubishi Tanabe Pharma has withdrawn its marketing authorization application for its free-radical scavenger edaravone, which the company submitted to the European Medicines Agency (EMA) in April last year for the suppression of functional disorders in amyotrophic lateral sclerosis (ALS), it...read more